Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months

Kazuhiko Ogawa, Katsumasa Nakamura, Tomonari Sasaki, Hiroshi Onishi, Masahiko Koizumi, Masayuki Araya, Nobutaka Mukumoto, Michihide Mitsumori, Teruki Teshima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: To analyze retrospectively the results of postoperative radiotherapy for localized prostate cancer and to investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcome after radiotherapy. Patients and Methods: Seventy-six patients with localized prostate cancer treated with postoperative radiotherapy were retrospectively reviewed. Total radiation doses ranged from 50 to 70 Gy (median: 60 Gy), and the median follow-up period for all 76 patients was 47.9 months (range, 12.4-101.3 months). Results: The 5-year actuarial overall survival, progression-free survival, biochemical relapse-free survival (BRFS) and local control rates in all 76 patients after radiotherapy were 86.1%, 77.8%, 80.0% and 92.2%, respectively. Distant metastases and/or regional lymph node metastases developed in 11 patients (14%) after radiotherapy, while local progression was observed in only 5 patients (7%). Of all 76 patients, the median nPSA12 in patients with biochemical failure and that in patients without biochemical failure were 1.16 ng/ml and 0.05 ng/ml, respectively. The 5-year BRFS rates in patients with low nPSA12 (<0.5 ng/ml) and those with high nPSA12 (≥0.5 ng/ml) were 92.7% and 42.2%, respectively (p<0.0001). In univariate analysis, nPSA12, pre-radiotherapy PSA, Karnofsky performance status and the use of chemotherapy had a significant impact on BRFS, and in multivariate analysis, nPSA12 alone was an independent prognostic factor for BRFS. Conclusion: Postoperative radiotherapy results in an excellent local control rate for localized prostate cancer and nPSA12 is predictive of biochemical failure after postoperative radiotherapy.

Original languageEnglish
Pages (from-to)4605-4613
Number of pages9
JournalAnticancer research
Volume29
Issue number11
Publication statusPublished - Nov 1 2009

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Radiotherapy
Recurrence
Survival
Neoplasm Metastasis
Karnofsky Performance Status
Disease-Free Survival
Multivariate Analysis
Survival Rate
Lymph Nodes
Radiation
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Postoperative radiotherapy for localized prostate cancer : Clinical significance of nadir prostate-specific antigen value within 12 months. / Ogawa, Kazuhiko; Nakamura, Katsumasa; Sasaki, Tomonari; Onishi, Hiroshi; Koizumi, Masahiko; Araya, Masayuki; Mukumoto, Nobutaka; Mitsumori, Michihide; Teshima, Teruki.

In: Anticancer research, Vol. 29, No. 11, 01.11.2009, p. 4605-4613.

Research output: Contribution to journalArticle

Ogawa, K, Nakamura, K, Sasaki, T, Onishi, H, Koizumi, M, Araya, M, Mukumoto, N, Mitsumori, M & Teshima, T 2009, 'Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months', Anticancer research, vol. 29, no. 11, pp. 4605-4613.
Ogawa, Kazuhiko ; Nakamura, Katsumasa ; Sasaki, Tomonari ; Onishi, Hiroshi ; Koizumi, Masahiko ; Araya, Masayuki ; Mukumoto, Nobutaka ; Mitsumori, Michihide ; Teshima, Teruki. / Postoperative radiotherapy for localized prostate cancer : Clinical significance of nadir prostate-specific antigen value within 12 months. In: Anticancer research. 2009 ; Vol. 29, No. 11. pp. 4605-4613.
@article{04d895de143d4e41a2709f1dfd8e3f71,
title = "Postoperative radiotherapy for localized prostate cancer: Clinical significance of nadir prostate-specific antigen value within 12 months",
abstract = "Aim: To analyze retrospectively the results of postoperative radiotherapy for localized prostate cancer and to investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcome after radiotherapy. Patients and Methods: Seventy-six patients with localized prostate cancer treated with postoperative radiotherapy were retrospectively reviewed. Total radiation doses ranged from 50 to 70 Gy (median: 60 Gy), and the median follow-up period for all 76 patients was 47.9 months (range, 12.4-101.3 months). Results: The 5-year actuarial overall survival, progression-free survival, biochemical relapse-free survival (BRFS) and local control rates in all 76 patients after radiotherapy were 86.1{\%}, 77.8{\%}, 80.0{\%} and 92.2{\%}, respectively. Distant metastases and/or regional lymph node metastases developed in 11 patients (14{\%}) after radiotherapy, while local progression was observed in only 5 patients (7{\%}). Of all 76 patients, the median nPSA12 in patients with biochemical failure and that in patients without biochemical failure were 1.16 ng/ml and 0.05 ng/ml, respectively. The 5-year BRFS rates in patients with low nPSA12 (<0.5 ng/ml) and those with high nPSA12 (≥0.5 ng/ml) were 92.7{\%} and 42.2{\%}, respectively (p<0.0001). In univariate analysis, nPSA12, pre-radiotherapy PSA, Karnofsky performance status and the use of chemotherapy had a significant impact on BRFS, and in multivariate analysis, nPSA12 alone was an independent prognostic factor for BRFS. Conclusion: Postoperative radiotherapy results in an excellent local control rate for localized prostate cancer and nPSA12 is predictive of biochemical failure after postoperative radiotherapy.",
author = "Kazuhiko Ogawa and Katsumasa Nakamura and Tomonari Sasaki and Hiroshi Onishi and Masahiko Koizumi and Masayuki Araya and Nobutaka Mukumoto and Michihide Mitsumori and Teruki Teshima",
year = "2009",
month = "11",
day = "1",
language = "English",
volume = "29",
pages = "4605--4613",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Postoperative radiotherapy for localized prostate cancer

T2 - Clinical significance of nadir prostate-specific antigen value within 12 months

AU - Ogawa, Kazuhiko

AU - Nakamura, Katsumasa

AU - Sasaki, Tomonari

AU - Onishi, Hiroshi

AU - Koizumi, Masahiko

AU - Araya, Masayuki

AU - Mukumoto, Nobutaka

AU - Mitsumori, Michihide

AU - Teshima, Teruki

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Aim: To analyze retrospectively the results of postoperative radiotherapy for localized prostate cancer and to investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcome after radiotherapy. Patients and Methods: Seventy-six patients with localized prostate cancer treated with postoperative radiotherapy were retrospectively reviewed. Total radiation doses ranged from 50 to 70 Gy (median: 60 Gy), and the median follow-up period for all 76 patients was 47.9 months (range, 12.4-101.3 months). Results: The 5-year actuarial overall survival, progression-free survival, biochemical relapse-free survival (BRFS) and local control rates in all 76 patients after radiotherapy were 86.1%, 77.8%, 80.0% and 92.2%, respectively. Distant metastases and/or regional lymph node metastases developed in 11 patients (14%) after radiotherapy, while local progression was observed in only 5 patients (7%). Of all 76 patients, the median nPSA12 in patients with biochemical failure and that in patients without biochemical failure were 1.16 ng/ml and 0.05 ng/ml, respectively. The 5-year BRFS rates in patients with low nPSA12 (<0.5 ng/ml) and those with high nPSA12 (≥0.5 ng/ml) were 92.7% and 42.2%, respectively (p<0.0001). In univariate analysis, nPSA12, pre-radiotherapy PSA, Karnofsky performance status and the use of chemotherapy had a significant impact on BRFS, and in multivariate analysis, nPSA12 alone was an independent prognostic factor for BRFS. Conclusion: Postoperative radiotherapy results in an excellent local control rate for localized prostate cancer and nPSA12 is predictive of biochemical failure after postoperative radiotherapy.

AB - Aim: To analyze retrospectively the results of postoperative radiotherapy for localized prostate cancer and to investigate the clinical significance of nadir prostate-specific antigen (PSA) value within 12 months (nPSA12) as an early estimate of clinical outcome after radiotherapy. Patients and Methods: Seventy-six patients with localized prostate cancer treated with postoperative radiotherapy were retrospectively reviewed. Total radiation doses ranged from 50 to 70 Gy (median: 60 Gy), and the median follow-up period for all 76 patients was 47.9 months (range, 12.4-101.3 months). Results: The 5-year actuarial overall survival, progression-free survival, biochemical relapse-free survival (BRFS) and local control rates in all 76 patients after radiotherapy were 86.1%, 77.8%, 80.0% and 92.2%, respectively. Distant metastases and/or regional lymph node metastases developed in 11 patients (14%) after radiotherapy, while local progression was observed in only 5 patients (7%). Of all 76 patients, the median nPSA12 in patients with biochemical failure and that in patients without biochemical failure were 1.16 ng/ml and 0.05 ng/ml, respectively. The 5-year BRFS rates in patients with low nPSA12 (<0.5 ng/ml) and those with high nPSA12 (≥0.5 ng/ml) were 92.7% and 42.2%, respectively (p<0.0001). In univariate analysis, nPSA12, pre-radiotherapy PSA, Karnofsky performance status and the use of chemotherapy had a significant impact on BRFS, and in multivariate analysis, nPSA12 alone was an independent prognostic factor for BRFS. Conclusion: Postoperative radiotherapy results in an excellent local control rate for localized prostate cancer and nPSA12 is predictive of biochemical failure after postoperative radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=75149148108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149148108&partnerID=8YFLogxK

M3 - Article

C2 - 20032410

AN - SCOPUS:75149148108

VL - 29

SP - 4605

EP - 4613

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -